CliffBio
biologic

CYFENDUS

Anthrax Vaccine Adsorbed, Adjuvanted

Loss of exclusivityJuly 2035projected — 12-year biologic exclusivity estimate
CompanyEmergent Product Development Gaithersburg →View the full company profile on CliffBio

Drug detail

Brand nameCYFENDUS
Active ingredientAnthrax Vaccine Adsorbed, Adjuvanted
Strength100UG/ML
Dosage formInjection
RouteIntramuscular
ModalityBiologic
FDA approvalJuly 2023
Marketing statusRx

More from Emergent Product Development Gaithersburg

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

CYFENDUS patent cliff — loss of exclusivity July 2035 | CliffBio